GlassScriptPhysician profile
Jerry J Soung
NPI 1154318764
$12,785.65
in general payments reported to CMS, 2019-2025
45 companies · $73.44 in 2025
The $73.44 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $2,346 · 2021: $2,509 · 2022: $2,539 · 2023: $2,256 · 2024: $1,580 · 2025: $73.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887 · Education: $22.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,887.26 |
| Education | $22.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,858.83 | 2019-2024 | Farxiga, Lokelma, Airsupra |
| Vifor Pharma, INC. | $1,202.10 | 2019-2023 | Veltassa |
| Amgen INC. | $1,061.56 | 2019-2024 | Tavneos, Parsabiv, Krystexxa |
| Novo Nordisk INC | $957.33 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $646.75 | 2019-2022 | |
| Akebia Therapeutics INC | $580.20 | 2019-2022 | |
| Horizon Therapeutics Plc | $547.22 | 2021-2023 | Krystexxa |
| Gilead Sciences, INC. | $536.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.05 | 2019-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $523.27 | 2019-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $512.42 | 2019-2024 | Jynarque, Rexulti |
| Glaxosmithkline, LLC. | $413.75 | 2021-2025 | Benlysta, Jesduvroq, Trelegy Ellipta |
| Fresenius USA Marketing, INC. | $381.62 | 2021-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $351.13 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $349.43 | 2021-2024 | Lupkynis |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Soung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.